Cequent wraps first venture round

It took a few months, but Cequent Pharmaceuticals--which is developing RNAi-based treatments--has completed its Series A round of financing with a total of $9 million. Cequent plans to go into the clinic next year with an experimental therapy for patients genetically predisposed to colon cancer. Ampersand Ventures, Nexus Medical Partners, and the Novartis Option Fund all took part in the round.

- see this release
- here's the report from Red Herring

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.